Characterization of drug specificity by pharmacokinetic analysis in gene knockout mice

Journal of Clinical Pharmacology

Volumn 39, Issue 8 SUPPL., 1999, Pages

  Piwnica Worms, David ^a   Marmion, Mary ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MALLINCKRODT PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; RADIOPHARMACEUTICAL AGENT;

ANIMAL; DIAGNOSTIC IMAGING; DRUG SCREENING; GENETICS; METABOLISM; MOUSE; MOUSE MUTANT; MULTIDRUG RESISTANCE; NEOPLASM; REVIEW; SENSITIVITY AND SPECIFICITY; TRANSGENIC MOUSE;

ANIMALS; DIAGNOSTIC IMAGING; DRUG EVALUATION; DRUG RESISTANCE, MULTIPLE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOPLASMS; P-GLYCOPROTEINS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY;

EID: 0033172826     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1999.tb05935.x     Document Type: Article

References (26)

1. Viney J: Transgenic and gene knockout mice in cancer research. Cancer Metastasis Rev 1995;14:77-90.
2. Payne R, Johnson M, Grant J, Strauss A: Toward a molecular understanding of congenital heart disease. Circulation 1995;91:494-504.
3. Nizielski S, et al: Animal models for studying the genetic basis of metabolic regulation. J Nutrition 1996;126:2697-2708.
4. Rosenberg M: Gene knockout and transgenic technologies in risk assessment: the next generation. Molecular Carcinogenesis 1997;20:262-274.
5. Gros P, Ben Neriah Y, Croop JM, Housman DE: Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 1986;323:728-731.
6. Bosch I, Croop J: P-glycoprotein multidrug resistance and cancer. Biochim Biophys Acta 1996;1288:F37-F54.
7. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427.
8. Ford JM, Hait WN: Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990;42:155-199.
9. Gaveriaux C, Boesch D, Jachez B: PSC 833 a non-immunosuppressive cyclosporin analog, is a very potent multidrug-resistance modifier. J Cell Pharmacol 1991;2:225-234.
10. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T: In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993;53:4595-4602.
11. Dantzig A, et al: Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 1996;56:4171-4179.
12. Germann U, Ford P, Schlakhter D, Mason V, Harding M: Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209, and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP. Anticancer Drugs 1997;8:141-155.
13. Homolya L, et al: Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem 1993;268:21493-21496.
14. Del Vecchio S, et al: In vivo detection of multidrug resistance (MDR1) phenotype by technetium-99m-sestamibi scan in untreated breast cancer patients. Eur J Nucl Med 1997;24:150-159.
15. Ciarmiello A, et al: Tumor clearance of technetium-99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 1998;16:1677-1683.
16. Taki J, et al: Assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy. J Nucl Med 1998;39:1179-1184.
17. Piwnica-Worms D, et al: Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993;53:977-984.
18. Rao W, Chiu ML, Kronauge JF, Piwnica-Worms D: Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-SESTAMIBl. J Nucl Med 1994;35:510-515.
19. Piwnica-Worms D, Rao V, Kronauge J, Croop J: Characterization of multidrug-resistance P-glycoprotein transport function with an organotechnetium cation. Biochemistry 1995;34:12210-12220.
20. Ballinger JR, et al: Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: in vitro studies in multidrug-resistant breast tumor cells. J Nucl Med 1996;37:1578-1582.
21. Jurisson SS, Dancey K, McPartlin M, Tasker PA, Deutsch E: Synthesis, characterization, and electrochemical properties of technetium complexes containing both tetradentate Schiff base and monodentate tertiary phosphine ligands: single-crystal structure of trans-(N,N′-ethylenebis(acetylacetone iminato))bis(triphenylphosphine)technetium(III) hexafluorophosphate. Inorg Chem 1984;23:4743-4749.
22. Deutsch E, et al: Development of nonreducible technetium-99m(III) cations as myocardial perfusion imaging agents: initial experience in humans. J Nucl Med 1987;28:1870-1880.
23. Crankshaw C, et al: Novel Tc(III)-Q-complexes for functional imaging of the multidrug resistance (MDR1) P-glycoprotein. J Nuc Med 1998;39:77-86.
24. Herman LW, et al: Novel hexakis(areneisonitrile)technetium(I) complexes as radioligands targeted to the multidrug resistance P-glycoprotein. J Med Chem 1995;38:2955-2963.
25. Luker G, Rao V, Crankshaw C, Dahlheimer J, Piwnica-Worms D: Characterization of phosphine complexes of technetium (III) as transport substrates of the multidrug resistance (MDR1) P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier. Biochemistry 1997;36:14218-14227.
26. Cherry S, et al: MicroPET: a high resolution PET scanner for imaging small animals. IEEE Trans Nucl Sci 1997;44:1161-1166.